Ultragenyx reports positive phase 3 results for OTC deficiency gene therapy

March 12, 2026 8:30 AM

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) reported positive results from its Phase 3 study of DTX301, an investigational gene therapy for ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found